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Previous animal experiments have indicated that administration of 
fluoxetine and simvastatin at 20-26 hours post-stroke decreases the volume of 
ischemic infarcts. This experiment expanded on previous experiments by adding 
ascorbic acid to the post-stroke regimen, initiating simvastatin pre-stroke, and 
adding a third initiation time frame (48-54 hours). 
Male retired breeder Sprague-Dawley rats were on simvastatin for 7 days 
prior to stroke induction. Combined medications of 5 milligrams/kilogram of 
fluoxetine, 1 milligram/kilogram of simvastatin and 20 milligrams/kilogram of 
ascorbic acid were orally administered at 6-12 hours, 20-26 hours, or 48-54 hours, 
respectively, following stroke induction.  
Adult rats that were treated 20-26 hours post-stroke showed a decrease in 
infarct volume (15.67 ± 5.622 millimeters cubed, P=0.0098) compared to the 
control.  The combination of simvastatin, fluoxetine and ascorbic acid decreased the 
relative risk (RR=0.3704 (95% confidence interval 0.0987 to 1.3905, p-value = 
0.1411) of bleeding after ischemic stroke if initiated 20-26 hours after stroke 
induction in rats.  
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rat  scope  slide  section  area (mm2)  volume (mm3) 
852  2  4  1  21.463 6.4389 
852  2  4  2  16.471 4.9413 
852  2  4  3  12.316 3.6948 
852  2  4  5  17.255 5.1765 
852  2  4  6  10.233 3.0699 
852  Number of tissue sections: 5  23.3214 
853  2  1  1  5.456 1.6368 
853  2  1  2  3.551 1.0653 
853  2  1  3  2.489 0.7467 
853  2  1  4  7.094 2.1282 
853  2  2  1  3.023 0.9069 
853  2  2  2  5.179 1.5537 
853  2  2  3  8.372 2.5116 
853  2  2  4  2.874 0.8622 
853  2  2  5  7.393 2.2179 
853  2  3  1  6.74 2.022 
853  2  3  2  6.885 2.0655 
853  2  3  3  9.708 2.9124 
853  2  4  2  0.726 0.2178 
853  2  4  3  0.638 0.1914 
853  Number of tissue sections: 14  21.0384 
854  2  1  1  2.361 0.7083 
854  2  1  2  11.178 3.3534 
854  2  1  3  12.762 3.8286 
854  2  2  1  8.356 2.5068 
854  2  2  2  7.604 2.2812 
854  2  2  3  8.258 2.4774 
854  2  2  4  5.874 1.7622 
854  2  2  5  5.01 1.503 
854  2  3  2  3.265 0.9795 
854  2  3  3  1.655 0.4965 
854  2  3  4  3.873 1.1619 
854  2  4  1  4.77 1.431 
854  2  4  2  4.459 1.3377 
854  2  4  3  8.312 2.4936 
854  2  4  4  8.319 2.4957 
854  Number of tissue sections: 15  28.8168 
855  2  1  1  1.136 0.3408 
855  Number of tissue sections: 1  0.3408 
856  2  1  1  25.441 7.6323 
856  2  1  3  10.528 3.1584 
856  2  1  4  12.752 3.8256 
856  2  2  1  11.542 3.4626 
	 41
856  2  2  2  12.157 3.6471 
856  2  2  3  10.772 3.2316 
856  2  2  4  10.532 3.1596 
856  2  2  5  14.347 4.3041 
856  2  3  1  10.504 3.1512 
856  2  3  2  11.225 3.3675 
856  2  3  3  14.339 4.3017 
856  2  3  4  10.439 3.1317 
856  2  3  5  9.143 2.7429 
856  Number of tissue sections: 13  49.1163 
857  2  1  1  4.662 1.3986 
857  2  1  3  1.448 0.4344 
857  2  1  4  1.124 0.3372 
857  2  2  1  0.952 0.2856 
857  2  2  2  1.462 0.4386 
857  2  2  5  4.308 1.2924 
857  2  4  1  5.255 1.5765 
857  Number of tissue sections: 7  5.7633 
859  2  1  1  13.398 4.0194 
859  2  1  2  9.49 2.847 
859  2  1  3  10.83 3.249 
859  2  1  4  13.894 4.1682 
859  2  1  5  15.839 4.7517 
859  2  3  1  1.036 0.3108 
859  2  3  2  2.479 0.7437 
859  2  3  3  8.869 2.6607 
859  2  3  4  5.666 1.6998 
859  2  3  6  3.722 1.1166 
859  2  3  7  2.711 0.8133 
859  Number of tissue sections: 11  26.3802 
861  2  1  4  4.284 1.2852 
861  2  2  3  4.394 1.3182 
861  2  3  2  3.391 1.0173 
861  2  3  3  4.635 1.3905 
861  2  4  5  5.294 1.5882 
861  Number of tissue sections: 5  6.5994 
862  2  1  2  2.538 0.7614 
862  2  1  3  2.948 0.8844 
862  2  1  4  3.775 1.1325 
862  2  2  1  2.385 0.7155 
862  2  2  3  3.996 1.1988 
862  2  2  4  3.411 1.0233 
862  2  3  1  3.82 1.146 
862  2  3  2  4.5 1.35 
862  2  3  4  3.495 1.0485 
862  2  4  1  3.53 1.059 
	 42
862  2  4  3  4.398 1.3194 
862  Number of tissue sections: 11  11.6388 
864  2  1  3  1.104 0.3312 
864  2  2  3  1.644 0.4932 
864  2  3  4  0.962 0.2886 
864  Number of tissue sections: 3  1.113 
865  2  1  1  11.746 3.5238 
865  2  1  2  13.521 4.0563 
865  2  2  1  11.526 3.4578 
865  2  2  2  11.833 3.5499 
865  2  2  3  8.788 2.6364 
865  2  2  4  12.153 3.6459 
865  2  3  1  15.131 4.5393 
865  2  3  2  9.445 2.8335 
865  2  3  3  7.442 2.2326 
865  2  3  4  10.843 3.2529 
865  2  4  1  8.734 2.6202 
865  2  4  2  7.307 2.1921 
865  2  4  3  12.005 3.6015 
865  2  4  4  9.919 2.9757 
865  Number of tissue sections: 14  45.1179 
866  2  1  1  6.252 1.8756 
866  2  1  2  4.622 1.3866 
866  2  1  3  3.425 1.0275 
866  2  2  2  5.803 1.7409 
866  2  2  3  7.219 2.1657 
866  2  3  1  2.008 0.6024 
866  2  4  2  0.866 0.2598 
866  Number of tissue sections: 7  9.0585 
868  2  5  1  12.444 3.7332 
868  2  5  2  16.536 4.9608 
868  2  5  3  12.643 3.7929 
868  Number of tissue sections: 3  12.4869 
869  2  1  3  4.428 1.3284 
869  2  1  4  2.617 0.7851 
869  2  1  5  6.044 1.8132 
869  2  2  1  5.933 1.7799 
869  2  2  2  2.101 0.6303 
869  Number of tissue sections: 5  6.3369 
870  2  2  3  1.212 0.3636 
870  2  5  1  2.066 0.6198 
870  2  5  2  1.069 0.3207 
870  2  5  3  1.824 0.5472 
870  2  5  4  1.335 0.4005 
870  Number of tissue sections: 5  2.2518 
872  2  2  1  6.902 2.0706 
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872  2  2  4  1.914 0.5742 
872  2  3  5  7.319 2.1957 
872  2  4  1  13.332 3.9996 
872  Number of tissue sections: 4  8.8401 
873  2  1  1  13.202 3.9606 
873  2  1  2  9.656 2.8968 
873  2  1  3  10.082 3.0246 
873  2  1  4  13.786 4.1358 
873  2  4  1  9.813 2.9439 
873  2  4  2  17.651 5.2953 
873  2  4  4  8.76 2.628 
873  2  5  1  20.266 6.0798 
873  2  5  2  19.791 5.9373 
873  2  5  3  11.7 3.51 
873  2  5  4  12.552 3.7656 
873  Number of tissue sections: 11  44.1777 
874  2  1  1  7.26 2.178 
874  2  1  2  4.362 1.3086 
874  2  1  3  6.253 1.8759 
874  2  1  4  6.001 1.8003 
874  2  2  2  2.098 0.6294 
874  2  2  4  4.63 1.389 
874  2  4  4  2.712 0.8136 
874  2  6  1  5.577 1.6731 
874  2  6  3  3.533 1.0599 
874  2  6  4  9.384 2.8152 
874  Number of tissue sections: 10  15.543 
875  2  1  2  5.907 1.7721 
875  2  1  4  4.101 1.2303 
875  2  2  1  9.716 2.9148 
875  2  2  2  10.891 3.2673 
875  2  2  3  13.238 3.9714 
875  2  2  4  8.505 2.5515 
875  2  2  5  12.712 3.8136 
875  2  3  1  11.763 3.5289 
875  2  3  2  9.777 2.9331 
875  2  3  3  8.104 2.4312 
875  2  3  4  6.664 1.9992 
875  2  3  5  10.576 3.1728 
875  2  4  1  5.493 1.6479 
875  2  4  2  11.057 3.3171 
875  2  4  3  10.597 3.1791 
875  2  4  4  8.299 2.4897 
875  2  4  5  13.064 3.9192 
875  Number of tissue sections: 17  48.1392 
876  2  1  1  2.907 0.8721 
	 44
876  2  2  1  1.283 0.3849 
876  2  3  1  1.15 0.345 
876  2  4  5  2.533 0.7599 
876  2  5  1  2.9 0.87 
876  2  5  3  2.017 0.6051 
876  2  5  4  2.721 0.8163 
876  Number of tissue sections: 7  4.6533 
879  1  2  3  31.983 9.5949 
879  1  2  4  37.966 11.3898 
879  1  3  1  38.465 11.5395 
879  1  3  2  38.277 11.4831 
879  2  1  1  12.879 3.8637 
879  2  1  2  12.73 3.819 
879  2  1  3  3.996 1.1988 
879  2  2  5  1.336 0.4008 
879  Number of tissue sections: 8  53.2896 
880  1  1  1  14.565 4.3695 
880  1  1  3  16.771 5.0313 
880  1  1  5  9.486 2.8458 
880  1  2  1  10.373 3.1119 
880  1  2  2  24.375 7.3125 
880  1  2  3  3.19 0.957 
880  1  2  4  7.284 2.1852 
880  1  2  5  5.913 1.7739 
880  1  3  4  4.593 1.3779 
880  Number of tissue sections: 9  28.965 
881  1  1  1  18.846 5.6538 
881  1  1  2  15.932 4.7796 
881  1  1  4  18.24 5.472 
881  1  1  5  29.651 8.8953 
881  1  2  1  18.908 5.6724 
881  1  2  2  36.617 10.9851 
881  1  2  3  42.935 12.8805 
881  1  2  4  17.879 5.3637 
881  Number of tissue sections: 8  59.7024 
883  1  1  1  5.161 1.5483 
883  1  1  2  8.286 2.4858 
883  1  1  3  7.551 2.2653 
883  1  2  2  8.081 2.4243 
883  1  3  1  9.714 2.9142 
883  1  3  3  7.737 2.3211 
883  Number of tissue sections: 6  13.959 
884  1  1  2  10.285 3.0855 
884  1  1  4  37.974 11.3922 
884  1  2  1  57.457 17.2371 
884  1  2  2  35.034 10.5102 
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884  1  2  3  62.457 18.7371 
884  1  2  4  70.882 21.2646 
884  1  3  1  15.813 4.7439 
884  1  3  2  46.98 14.094 
884  1  3  3  62.476 18.7428 
884  Number of tissue sections: 9  119.8074 
885  1  2  3  28.463 8.5389 
885  Number of tissue sections: 1  8.5389 
886  1  1  2  8.004 2.4012 
886  1  1  3  14.697 4.4091 
886  1  1  4  14.041 4.2123 
886  1  2  2  7.287 2.1861 
886  1  3  3  8.207 2.4621 
886  1  4  4  8.958 2.6874 
886  Number of tissue sections: 6  18.3582 
887  1  1  3  19.506 5.8518 
887  1  1  4  19.664 5.8992 
887  1  2  1  17.272 5.1816 
887  1  2  3  9.071 2.7213 
887  1  2  5  4.649 1.3947 
887  1  3  2  22.716 6.8148 
887  1  3  3  18.22 5.466 
887  1  3  4  31.54 9.462 
887  Number of tissue sections: 8  42.7914 
888  1  1  2  3.411 1.0233 
888  1  1  4  1.553 0.4659 
888  1  2  1  8.358 2.5074 
888  1  2  2  5.387 1.6161 
888  1  2  4  2.713 0.8139 
888  1  4  1  2.616 0.7848 
888  1  4  3  1.97 0.591 
888  Number of tissue sections: 7  7.8024 
889  1  1  1  9.328 2.7984 
889  2  1  2  6.988 2.0964 
889  2  3  5  9.878 2.9634 
889  Number of tissue sections: 3  7.8582 
891  1  1  1  19.764 5.9292 
891  1  1  2  33.341 10.0023 
891  1  1  3  30.537 9.1611 
891  1  1  4  44.716 13.4148 
891  1  1  5  15.236 4.5708 
891  1  2  1  48.479 14.5437 
891  1  2  2  47.514 14.2542 
891  1  2  3  16.004 4.8012 
891  1  2  4  25.751 7.7253 
891  1  2  5  14.42 4.326 
	 46
891  1  2  6  21.569 6.4707 
891  Number of tissue sections: 11  95.1993 
892  2  1  1  10.004 3.0012 
892  2  1  2  7.717 2.3151 
892  2  1  3  11.019 3.3057 
892  2  1  5  8.608 2.5824 
892  2  2  1  11.685 3.5055 
892  2  2  2  21.28 6.384 
892  2  2  3  14.209 4.2627 
892  2  2  4  11.638 3.4914 
892  2  2  5  18.958 5.6874 
892  2  3  2  13.595 4.0785 
892  2  3  3  16.017 4.8051 
892  Number of tissue sections: 11  43.419 
893  2  1  1  13.838 4.1514 
893  2  1  2  11.016 3.3048 
893  2  1  3  17.986 5.3958 
893  2  1  4  17.936 5.3808 
893  2  2  1  5.626 1.6878 
893  2  2  2  17.32 5.196 
893  2  2  3  16.927 5.0781 
893  2  2  4  17.28 5.184 
893  2  3  1  11.222 3.3666 
893  2  3  2  8.914 2.6742 
893  Number of tissue sections: 10  41.4195 
895  2  1  1  4.376 1.3128 
895  2  1  2  12.639 3.7917 
895  2  1  3  9.656 2.8968 
895  2  1  4  10.784 3.2352 
895  2  1  5  2.756 0.8268 
895  2  2  1  9.218 2.7654 
895  2  2  2  11.659 3.4977 
895  2  2  3  3.834 1.1502 
895  2  2  4  16.357 4.9071 
895  2  2  5  10.292 3.0876 
895  2  3  1  13.429 4.0287 
895  2  3  2  11.561 3.4683 
895  2  3  3  8.663 2.5989 
895  2  3  4  13.227 3.9681 
895  Number of tissue sections: 14  41.5353 
896  2  1  3  9.251 2.7753 
896  2  1  4  6.989 2.0967 
896  2  1  5  3.442 1.0326 
896  Number of tissue sections: 3  5.9046 
897  2  1  1  11.29 3.387 
897  2  1  2  18.493 5.5479 
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897  2  1  3  19.626 5.8878 
897  2  1  4  16.781 5.0343 
897  2  2  1  12.817 3.8451 
897  2  2  3  8.457 2.5371 
897  2  3  1  26.826 8.0478 
897  2  3  2  27.437 8.2311 
897  2  3  3  11.888 3.5664 
897  2  3  4  7.124 2.1372 


















































18.3582	 23.3214	 11.6388	 15.543	
42.7914	 21.0384	 1.113	 48.1392	
7.8024	 28.8168	 45.1179	 4.6533	
7.8582	 0.3408	 9.0585	 53.2896	
95.1993	 49.1163	 12.4869	 28.965	
43.419	 5.7633	 6.3369	 59.7024	
41.4195	 26.3802	 2.2518	 13.959	
41.5353	 	 8.8401	 119.8074	
5.9046	 	 44.1777	 8.5389	









































































































































































































































































































































































Hemorrhagic  5 6 11
No 
hemorrhagic  3 4 7




Hemorrhagic  5 2 7
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hemorrhagic  3 7 10




Hemorrhagic  5 5 10
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hemorrhagic  3 4 7




Hemorrhagic  2 6 8
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hemorrhagic  7 4 11




Hemorrhagic  2 5 7
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Hemorrhagic  5 6 11
No 
hemorrhagic  4 4 8
Total  9 10 19
P‐value: 
1.0000 
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IV.	DISCUSSION	
	
RESULTS	SUMMARY	
	 The	results	of	this	experiment	indicate	that	the	administration	of	post‐
stroke	pharmacologic	agents	affects	the	size	of	ischemic	infarcts.	Another	
conclusion	that	can	be	drawn	is	that	the	timing	of	administration	is	pertinent	
when	administering	post‐stroke	pharmacologic	agents	in	terms	of	the	size	of	
ischemic	infarcts.	None	of	the	pharmacologic	interventions	seemed	to	make	any	
statistically	significant	difference	in	terms	of	the	frequency	of	hemorrhagic	
transformations,	however.	Finally,	the	results	of	this	experiment	call	into	
question	the	effectiveness	of	pre‐stroke	simvastatin	in	reducing	the	size	of	
ischemic	infarcts,	or	in	preventing	hemorrhagic	transformations.		
	
Effects	of	Post‐Stroke	Pharmacologic	Regimen		
	 Rats	who	underwent	a	pre‐stroke	regimen	of	simvastatin,	followed	by	a	
post‐stroke	pharmacologic	regimen	of	fluoxetine,	simvastatin	and	ascorbic	acid	
that	was	initiated	at	20‐26	hours	post‐stroke	saw	a	statistically	significant	
decrease	in	infarct	size	when	compared	to	the	control	group	(Graph	2).	Animals	
who	were	given	fluoxetine,	simvastatin	and	ascorbic	acid	6‐12	hours	post	stroke	
or	48‐54	hours	post‐stroke	did	not	show	a	statistically	significant	difference	
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when	compared	to	the	control	group.	These	findings	are	consistent	with	
previous	studies	that	this	lab	has	done	(Corbett	et	al,	2015).		
In	a	previous	study	from	this	lab,	the	mean	of	the	infarct	volumes	from	a	
group	of	rats	that	were	treated	with	5	milligrams/kilogram	of	fluoxetine	and	one	
milligram/kilogram	of	simvastatin	20‐26	hours	post‐stroke	was	shown	to	be	less	
than	that	of	an	untreated	control	group	(3.051	±	0.3447	millimeters	cubed	for	
the	treated	group	versus	6.277	±	0.14	millimeters	cubed	for	the	control	group	
that	was	given	nothing,	pre	or	post‐stroke)	(Balch	et	al,	2015).	Although	the	
eventual	results	of	this	experiment	are	similar	to	those	of	the	previous	
experiment,	it	is	worth	noting	that	the	size	of	the	infarcts	in	this	experiment	are	
considerably	larger,	both	for	the	treated	groups	and	the	control	groups,	when	
compared	to	the	previous	experiment.		 	
The	most	likely	explanation	is	that	the	previous	experiment	was	
conducted	for	90	days	post	stroke,	whereas	this	experiment	was	conducted	for	
only	six	days	post	stroke.	A	prolonged	period	of	post‐stroke	treatment	would	
have	allowed	for	a	greater	degree	of	neurogenesis	and	healing,	and	therefore,	
the	observable	size	of	the	infarct	would	be	smaller.		Another	possibility	is	that	
the	previous	study	from	this	lab	employed	female	rats,	while	the	current	study	
employed	male	rats.	There	are	a	litany	of	differences	between	male	and	female	
human	brains,	including	the	overall	size	of	the	brain,	the	size	of	various	areas,	
the	composition	of	neurons,	neurotransmitter	content,	receptor	morphology	and	
dendrite	receptors	(Joel	2011).	The	difference	between	male	and	female	
hormones	has	been	shown	to	play	a	significant	part	in	stroke	response.	When	
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comparing	male	rats,	pre‐menopausal	female	rats	and	female	rats	with	their	
ovaries	removed,	pre‐menopausal	female	rats	had	the	best	response	to	an	
induced	ischemic	stroke.	They	showed	greater	cerebral	blood	flow	and	smaller	
infarct	volumes	compared	to	the	other	two	groups.		This	difference	in	outcomes	
was	attributed	to	the	production	of	endogenous	estrogen	(Alkayed	et	al,	1998).	
Attempting	to	ascertain	the	exact	anatomical	or	physiologic	reason	that	male	rat	
brains	suffer	from	larger	infarcts	is	beyond	the	scope	of	this	experiment,	but	an	
appropriate	first	step	would	be	to	conduct	parallel	trials	that	are	exactly	alike,	
with	the	only	difference	being	that	one	trial	employs	male	rats	and	one	trial	
employs	female	rats.		
This	experiment	also	employed	different	pharmacologic	agents	at	
different	time	periods.	In	the	previous	experiment,	there	was	no	pre‐stroke	
treatment	with	any	pharmacologic	agents,	whereas	in	this	experiment,	all	rats	
were	given	a	one	milligram/kilogram	dose	of	simvastatin	once	a	day	for	seven	
days.	Furthermore,	this	current	experiment	introduced	a	20	milligram/kilogram	
dose	of	vitamin	C,	whereas	the	previous	experiment	did	not	include	vitamin	C.	It	
is	difficult	to	tell	whether	or	not	the	introduction	of	new	pharmacologic	agents	
had	any	bearing	on	the	size	of	the	infarcts	compared	to	previous	experiments.	
The	only	way	to	be	sure	would	be	to	run	experiments	directly	comparing	groups	
who	received	pre‐stroke	simvastatin	with	those	that	did	not,	and	groups	that	
received	vitamin	C	with	those	that	did	not.		
The	success	of	the	pharmacologic	regimen	in	reducing	the	size	of	an	
ischemic	infarct	can	be	attributed	to	the	aspects	of	the	agents	that	were	
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previously	discussed.	Whether	it	is	anti‐inflammation,	neurogenesis,	or	
increased	cerebral	blood	flow,	the	pharmacologic	agents	that	were	employed	
have	numerous	properties	that	would	make	them	ideal	for	post‐stroke	
treatment.		These	findings	are	pertinent	because	the	amount	of	damage	that	a	
stroke	causes	has	direct	implications	on	the	capabilities	of	the	individual	post‐
stroke.	Because	the	functions	of	the	brain	are	localized	to	various	areas,	the	
more	brain	tissue	that	is	damaged,	the	more	deficits	an	individual	will	have.	In	
theory,	limiting	the	amount	of	tissue	that	is	damaged	by	a	stroke	will	limit	the	
disabilities	of	the	individual.		
	
Effects	of	Timing	the	Initiation	of	Pharmacologic	Treatment	on	Stroke	Infarct	
Area			
	 Although	the	pharmacologic	regimen	employed	has	shown	to	be	effective	
in	limiting	the	size	of	cerebral	infarcts,	there	is	another	factor	that	is	important	
to	consider	when	employing	pharmacologic	agents	post‐stroke.	As	can	be	
observed	from	the	data,	the	timing	of	the	initiation	of	the	pharmacologic	
regimen	is	pertinent.	The	20‐26	hour	window	was	the	only	time	frame	that	
yielded	a	statistically	significant	decrease	in	infarct	size.	The	pharmacologic	
regimen	administered	before	and	after	this	window	did	not	yield	statistically	
significant	results.		
This	pattern	was	also	shown	in	previous	experiments	from	this	lab.	In	a	
previous	experiment,	rats	who	were	given	5	milligrams/kilogram	of	fluoxetine	
and	one	milligram/kilogram	at	6‐12	hours	post‐stroke	had	larger	infarct	
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volumes	compared	to	the	untreated	control	groups	(15.24	±	4.26	millimeters	
cubed	for	the	treated	group	versus	9.775	±	2.786	millimeters	cubed	for	the	
untreated	control	group)	(Balch	et	al,	2015).	Although	the	group	1	rats	did	not	
have	larger	infarcts	then	the	control	group	in	this	experiment,	there	was	not	a	
statistically	significant	decrease	in	their	mean	infarct	volumes.	There	are	
multiple	possible	reasons	for	this.	First,	five	of	the	eight	infarcts	associated	with	
group	1	in	this	experiment	had	hemorrhagic	transformations	present	(Figure	2).	
As	noted	previously,	simvastatin	has	anti‐thrombotic	properties	(Endres	et	al,	
1998).	One	possibility	is	that	the	early	introduction	of	simvastatin	inhibits	
thrombosis	within	cerebral	tissue	and	predisposes	post‐infarct	tissue	to	
bleeding.	It	is	worth	noting	that	when	the	experiment	was	first	started,	the	initial	
pre‐stroke	simvastatin	dose	was	2	milligrams/kilogram	for	all	rats.	Three	of	the	
rats	developed	significant	nosebleeds;	the	simvastatin	was	immediately	stopped	
and	the	experiment	was	delayed	for	a	week	in	order	for	the	simvastatin	to	fully	
excreted	by	the	rats.	The	experiment	was	restarted	with	lowering	the	dose	of	
pre‐stroke	simvastatin	to	1	milligram/kilogram,	and	no	complications	arose.	The	
anti‐thrombotic	properties	of	simvastatin	are	global,	and	if	elevated	doses	are	
able	to	cause	bleeding	from	healthy	mucosal	membranes,	it	is	possible	that	
statins	may	predispose	tissue	that	has	been	compromised	to	hemorrhagic	
transformations.		
	Also	as	previously	noted,	simvastatin	promotes	vascular	endothelial	
growth	factor,	a	primary	protein	for	vasculogenesis	(Chen	et	al,	2003).	If	
introduced	too	early,	vascular‐endothelial	growth	factor	may	promote	
	 73
vasculogenesis	into	tissue	whose	structure	is	compromised	by	an	ischemic	
infarct,	leading	to	a	collapse	of	new	blood	vessels	and	causing	a	secondary	
hemorrhagic	infarct.	Further	investigation	into	the	presence	of	vascular‐
endothelial	growth	factor	in	cerebral	tissue	that	has	been	treated	with	
simvastatin	would	be	warranted	in	order	to	confirm	this	hypothesis.		
	 Initiation	of	pharmacologic	agents	at	48‐54	hours	also	did	not	yield	a	
statistically	significant	decrease	in	infarct	size.	In	fact,	the	mean	of	the	volume	of	
the	infarcts	was	greater	for	group	3	when	compared	to	controls.	One	possible	
explanation	for	this	outcome	is	that	the	induction	of	the	pharmacologic	agents	
occurs	too	late	in	order	to	have	any	effect	on	post‐ischemic	neural	tissue.	As	
noted	previously,	fluoxetine	has	anti‐inflammatory	properties;	specifically,	it	
limits	the	migration	of	neutrophils	and	microglial	cells	into	a	post‐ischemic	
environment	(Lim	et	al,	2008).	During	inflammation,	neutrophils	arrive	within	
24	hours.	They	are	followed	by	T‐cells	and	macrophages	on	day	4,	and	then	
fibroblasts	on	day	7	(“Inflammation”	2016).	By	initiating	pharmacologic	
treatment	at	48‐54	hours,	the	window	of	opportunity	for	fluoxetine	to	affect	the	
migration	of	neutrophils	has	passed.	Fluoxetine	also	encourages	the	production	
of	antioxidants.	Many	of	these	white	blood	cells	are	sources	of	reactive	oxygen	
species;	by	administering	fluoxetine	too	late,	the	window	of	opportunity	for	
antioxidants	to	bind	to	reactive	oxygen	species	and	prevent	oxidative	damage	is	
missed	as	well.			
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Effect	of	Pre‐Stroke	Simvastatin	Treatment	
	 As	previously	noted,	there	is	a	body	of	evidence	that	suggests	the	
effectiveness	of	pre‐treatment	with	statins	concerning	post‐ischemic	stroke	
mortality	and	motor	function	(Endres	et	al,	1998;	Marti‐Fabregas	et	al,	2004;	
Jonsson	et	al,	2001).	One	of	the	proposed	hypotheses	of	this	experiment	was	to	
determine	whether	or	not	there	is	strong	evidence	that	indicates	pre‐treatment	
with	statins	has	any	bearing	on	ischemic	infarct	volume.		
For	this	experiment,	the	control	group	received	one	milligram/kilogram	
of	simvastatin	daily	for	seven	days	pre‐stroke.	The	mean	infarct	size	for	the	
control	group	was	35.57	±	8.632	millimeters	cubed.	The	size	of	these	infarcts	
was	considerable,	especially	when	compared	to	previous	experiments.	In	a	
previous	experiment,	two	control	groups	did	not	receive	any	pharmacologic	
treatment,	pre	or	post‐stroke.		The	infarct	volumes	for	those	control	groups	
were	6.277	±	0.14	millimeters	cubed	and	9.775	±	2.786	millimeters	cubed,	
respectively.	At	first	glance,	it	appears	that	pre‐stroke	simvastatin	actually	leads	
to	larger	stroke	volumes.		However,	it	is	difficult	to	compare	results	from	the	
previous	experiment	to	results	of	the	current	experiment.		
First,	the	previous	experiment	employed	Nissl	stain,	compared	to	the	
hematoxylin	and	eosin	stain	that	was	employed	for	the	current	experiment.	
Hematoxylin	and	eosin	clearly	color	the	invading	neutrophils,	microglia	and	
macrophages	(Figures	1	and	2).	The	delineation	of	the	infarct	damage	is	easy	to	
see	and	measure.	Nissl	stain,	however,	does	not	stain	the	invading	cells,	and	
therefore,	does	not	clearly	demarcate	the	borders	of	the	stroke.	Using	Nissl	stain	
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makes	exact	measurement	of	the	stroke	area	more	difficult.	In	addition,	many	of	
the	tissue	samples	from	the	previous	experiment	had	torn	at	the	site	of	the	
stroke	induction,	so	some	of	the	measurements	had	to	be	presumed.	Also,	and	
again	worth	noting,	the	previous	experiment	was	conducted	for	90‐days	post‐
stroke,	whereas	the	current	experiment	was	only	conducted	for	6	days	post‐
stroke.	Finally,	in	the	current	experiment,	six	of	the	10	control	tissue	samples	
showed	evidence	of	large	hemorrhagic	transformations	(Figure	2).	These	results	
are	somewhat	in	contradiction	to	previous	studies	that	suggested	that	statins	
were	neuro‐protective,	and	that	individuals	who	were	takings	statins	had	
greater	functional	improvement	and	lower	mortality	rates	post	stroke.		
	
Effect	of	Pharmacologic	Treatment	on	the	Frequency	of	Hemorrhagic	
Transformations	
Rats	who	were	given	a	pharmacologic	regimen	of	fluoxetine,	simvastatin	
and	vitamin	C	post‐stroke,	initiated	at	20‐26	hours,	showed	a	significant	
decrease	in	the	relative	risk	of	hemorrhagic	transformations.	Rats	who	were	
given	the	same	pharmacologic	regimen	at	6‐12	hours	and	at	48‐54	hours	did	not	
show	a	significant	increase	or	decrease	in	the	risk	of	hemorrhagic	
transformations.	The	relative	risk	value	is	a	ratio	that	determines	the	probability	
of	an	event	occurring	in	an	exposed	group	versus	an	unexposed	group.	Clinical	
trials	frequently	use	relative	risk	to	measure	the	efficacy	of	new	medications	
compared	to	old	medications.	It	can	also	be	used	to	track	the	probability	of	side	
effects.	A	relative	risk	equivalent	to	1	means	that	there	is	no	risk	difference	
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between	two	groups,	while	a	relative	risk	less	than	one	means	that	an	event	is	
less	likely	to	occur	in	the	exposed	group	compared	to	the	control,	and	a	relative	
risk	greater	than	one	means	that	an	event	is	more	likely	to	occur	in	the	exposed	
group	compared	to	the	control.		
When	compared	to	the	control,	groups	1	and	3	had	calculated	relative	
risks	at	1.0417	and	0.9259,	respectively.	Because	both	of	these	values	are	close	
to	one,	it	indicates	that	initiating	pharmacologic	agents	at	either	6‐12	or	48‐54	
hours	does	not	have	an	appreciable	affect	on	either	increasing	or	decreasing	the	
risk	of	a	hemorrhagic	transformation.	For	group	2,	the	relative	risk	was	0.3704.	
Although	this	data	would	suggest	that	the	20‐26	hour	window	is	the	“sweet	
spot”	concerning	reducing	the	risk	of	hemorrhagic	transformations,	the	p‐values	
for	these	relative	risk	calculations	are	greater	than	0.05,	so	it	is	difficult	to	draw	
definitive	conclusions	from	this	data.	One	possible	reason	for	the	high	p‐values	
could	be	attributed	to	the	small	sample	size.	By	increasing	the	number	of	test	
subjects,	the	resulting	data	may	yield	statistically	significant	p‐values.	
	 The	notion	that	20‐26	hours	is	the	proverbial	“sweet	spot”	concerning	
minimizing	the	risk	of	hemorrhagic	transformations	is	further	supported	by	the	
data	from	the	contingency	tables.	Contingency	tables	were	employed	to	analyze	
the	data	of	this	experiment	because	they	can	help	find	interrelations	between	
two	variables.	For	this	experiment,	the	two	variables	were	the	nature	of	the	
pharmacologic	interventions	(both	in	terms	of	the	medication	administered	and	
the	timing	of	the	administration)	and	the	presence	of	hemorrhagic	
transformations.	In	order	to	ascertain	whether	or	not	any	correlation	was	
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statistically	significant,	a	p‐value	must	be	calculated.	Fisher’s	exact	test	is	a	
methodology	of	analyzing	contingency	tables.	It	was	designed	to	analyze	
categorical	data	that	can	be	classified	in	two	different	ways,	hence	it’s	utility	in	
this	experiment.	It	is	most	commonly	employed	in	two‐by‐two	contingency	
tables,	and	when	the	sample	size	is	small.	It	also	allows	for	the	exact	calculation	
of	the	p‐value.		
The	majority	of	the	contingency	tables	yielded	a	p‐value	of	one	(Table	5).	
Only	contingency	tables	that	involved	group	2	yielded	lower	p‐values,	although	
the	p‐values	were	still	greater	than	0.05.	The	fact	that	the	p‐values	did	decrease	
when	groups	were	compared	to	group	2	indicates	that	there	is	a	trend	towards	
the	validity	of	the	idea	that	the	20‐26	hour	window	is	the	most	ideal	when	
concerning	limiting	the	risk	of	hemorrhagic	transformations.	Similar	to	the	
relative	risk	data,	however,	is	that	because	the	p‐values	are	greater	than	0.05,	
the	notion	that	the	20‐26	hour	window	is	the	most	ideal	can	only	be	inferred;	it	
cannot	be	a	definitive	conclusion.	Again,	increasing	the	sample	size	would	help	
to	truly	ascertain	whether	or	not	the	trends	indicated	in	this	experiment	are	
viable.		
	 The	biological	reasoning	behind	these	findings	is	most	likely	similar	to	
the	previously	mentioned	reasoning	behind	the	differences	in	infarct	volume.	As	
previously	noted,	simvastatin	has	multiple	properties	that	would	predispose	an	
individual	to	hemorrhagic	transformations	if	implemented	too	soon,	including	
anti‐platelet	and	pro‐vasculogenesis	properties	(Endres	et	al,	1998;	Chen	et	al,	
2003).	By	administering	the	pharmacologic	regimen	too	late,	the	window	to	
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inhibit	inflammation	is	missed.	White	blood	cells	migrate	into	the	ischemic	area	
and	release	reactive	oxygen	species	that	cause	oxidative	damage.	
(“Inflammation”	2016).	By	damaging	the	surrounding	tissue,	the	structural	
integrity	of	the	tissue	is	compromised	and	possibly	predisposed	to	hemorrhagic	
transformations.		
It	worth	noting,	however,	that	hemorrhagic	transformations	can	occur	
independent	of	pharmacologic	intervention.	A	prospective	study	of	humans	
showed	that	69%	of	individuals	with	confirmed	cardiogenic	ischemic	infarcts	
also	had	evidence	of	hemorrhagic	transformations	3	weeks	later	(Hornig	et	al,	
1993).	One	possible	reason	for	this	phenomenon	involves	metalloproteinases.	
Metalloproteinases	are	protease	enzymes	whose	catalytic	mechanisms	involve	
metal.	In	an	analysis	of	five	humans	who	had	died	of	ischemic	infarcts	with	
hemorrhagic	complications,	researchers	noted	a	significant	increase	in	the	
expression	of	the	cleaved	form	of	metalloproteinase‐9	in	the	areas	of	the	brain	
where	hemorrhagic	transformation	was	present,	compared	to	areas	without	
hemorrhagic	transformation	(Rosell	et	al,	2008).		Metalloproteinase‐9	degrades	
type	IV	collagen,	which	is	an	integral	component	of	the	basal	lamina.	The	basal	
lamina	is	one	of	the	primary	components	of	the	basement	membrane,	which	
separates	the	endothelial	cells	of	the	blood	vessels	from	the	extracellular	matrix.	
Degradation	of	type	IV	collagen	leads	to	the	degradation	of	the	basement	
membrane,	which	leads	to	the	eventual	rupture	of	the	blood	vessels	and	a	
hemorrhagic	transformation.	The	source	of	the	metalloproteinases	seems	to	be	
neutrophils,	as	there	was	a	strong	metalloproteinase‐9	positive	neutrophil	
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infiltration	near	the	ruptured	microvessels	(metalloproteinases	are	primarily	
found	in	stromal	cells,	which	are	the	connective	tissue	cells	of	any	organ)	(Rosell	
et	al,	2008).	This	conclusion	further	supports	the	hypothesis	that	the	anti‐
inflammatory	effects	of	fluoxetine	are	one	of	the	key	factors	in	reducing	the	
infarct	volume	and	hemorrhagic	transformation	frequency.		
	
FUTURE	EXPERIMENTS	
	 In	order	to	gain	a	better	understanding	of	the	results	of	this	experiment,	
there	are	several	possible	experiments	that	can	be	performed	in	the	future.	
	
Conduction	of	the	Same	Study	for	90	Days	
	 Part	of	the	difficulty	in	analyzing	the	results	of	this	study	is	the	disparate	
duration	of	this	experiment	compared	to	previous	experiments.	Because	the	
previous	experiment	from	this	lab	was	run	for	90	days,	while	this	experiment	
was	only	run	for	14	days,	it	can	be	difficult	to	compare	the	two	studies	and	make	
any	concrete	conclusions.	In	order	to	make	the	results	comparable,	this	same	
study	could	be	repeated	for	the	full	90	days.	Once	completed,	the	results	could	
be	used	to	ascertain	whether	or	not	vitamin	C,	when	used	in	conjunction	with	
fluoxetine	and	simvastatin,	has	any	bearing	on	infarct	size.	The	results	could	also	
be	used	to	truly	discern	whether	or	not	initiating	pharmacologic	agents	at	48‐54	
hours	is	effective	and	reducing	infarct	size.	Also,	by	re‐conducting	this	
experiment	with	male	rats	again,	any	true	differences	in	gender	concerning	the	
size	of	infarcts	could	be	ascertained.		
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Comparing	Groups	Who	Receive	Simvastatin	Pre‐Stroke	with	Those	Who	Do	Not	
For	this	experiment,	the	control	group	received	simvastatin	for	7	days	
pre‐stroke	and	six	days	post‐stroke.	Although	there	was	no	discernible	effect	on	
reducing	infarct	size,	there	cannot	be	any	concrete	conclusions	drawn	from	this	
data	about	pre‐stroke	simvastatin.	Moving	forward,	a	long‐term	study	
comparing	rats	that	do	not	receive	any	pharmacologic	intervention	to	rats	that	
receive	statins	pre‐stroke	would	provide	stronger	evidence	as	to	the	efficacy	of	
pre‐stroke	treatment	with	statins.		
At	the	minimum,	an	experiment	should	be	conducted	that	would	include	
a	pre‐stroke	treatment	regimen	with	simvastatin,	followed	by	a	post‐stroke	
regimen	of	fluoxetine	and	simvastatin	for	90	days.	The	results	of	this	experiment	
would	then	at	least	be	comparable	to	the	experiment	performed	in	2015.	A	
seven	day	pre‐stroke	treatment	regimen	may	also	not	be	adequate	enough	to	
properly	assess	whether	or	not	simvastatin	administered	pre‐stroke	has	any	
efficacy.	A	longer	course	of	pre‐stroke	simvastatin	(30	days,	for	example)	may	be	
necessary	to	be	able	to	apply	the	results	to	the	typical	experience	for	adult	
humans.	
It	is	also	worth	noting	that	the	rats	that	were	used	in	this	experiment	had	
normal	cholesterol	levels.	Normally,	adult	humans	are	prescribed	statins	when	
they	have	elevated	cholesterol	levels.	To	have	rats	with	normal	cholesterol	levels	
on	statins	pre‐stroke	does	not	accurately	reflect	the	environment	of	adult	
humans.		In	order	to	better	simulate	the	environment	that	represents	the	adult	
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human	population,	the	use	of	rats	that	have	elevated	cholesterol	levels	would	be	
warranted.	An	experiment	that	employed	two	parallel	groups	of	rats	(one	with	
elevated	cholesterol,	and	one	with	normal	cholesterol)	receiving	a	statin	pre‐
stroke	would	reveal	whether	pre‐stroke	cholesterol	levels	of	the	individuals	has	
any	affect	on	experiment	results.			
	
CONCLUSIONS	
	 The	results	of	this	experiment	generally	support	previous	results	from	
this	lab.	The	initiation	of	post‐stroke	fluoxetine,	simvastatin,	and	possibly	
vitamin	C	reduces	the	volume	of	ischemic	infarcts.	The	pharmacologic	regimen	
must	be	timed	appropriately,	however,	in	order	to	be	effective.	When	applied	too	
early,	or	too	late,	there	is	a	possible	predisposition	to	hemorrhagic	
transformations.	This	could	be	due	to	an	increase	in	vascular‐endothelial	growth	
factor,	or	an	inhibition	of	clotting	factors,	or	missing	the	window	for	inhibiting	
inflammation	and	reactive	oxygen	species.		
What	is	less	clear	is	whether	or	not	pre‐stroke	simvastatin	is	helpful	in	
reducing	the	size	of	ischemic	infarcts.	Although	analysis	of	patient	populations	
indicates	that	patients	who	are	on	statins	pre‐stroke	have	better	outcomes	post‐
stroke,	there	has	yet	to	be	a	definitive	biological	explanation	for	this	
phenomenon.	Although	the	data	from	this	experiment	indicates	that	pre‐stroke	
simvastatin	is	not	effective	in	reducing	infarct	volumes,	more	rigorous	testing	
involving	untreated	control	groups	and	extended	periods	of	experiment	time	are	
necessary	in	order	to	confirm	these	findings.		
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While	the	results	of	this	experiment	are	promising,	ultimately,	more	
experimentation	is	required	in	order	to	solidify	the	conclusions	drawn	from	this	
experiment.	A	full	90	day	trial	with	an	untreated	control	group,	a	group	treated	
with	pre‐stroke	and	post‐stroke	simvastatin,	and	a	group	treated	with	pre‐
stroke	simvastatin	plus	post‐stroke	fluoxetine,	simvastatin	and	vitamin	C	would	
be	the	next	logical	step	in	determining	the	effectiveness	of	these	pharmacologic	
agents.		
To	date,	there	are	no	documented	studies	that	employ	the	pharmacologic	
triad	that	this	experiment	employed.	The	strongest	clinical	evidence	for	the	
effectiveness	for	any	of	these	agents	comes	from	the	FLAME	trial	(Chollet	et	al,	
2011).	The	FLAME	trial	was	a	double	blinded,	randomized	placebo‐controlled	
trial	that	tested	the	efficacy	of	fluoxetine	on	the	improvement	of	motor	function	
in	patients	who	had	suffered	an	ischemic	stroke.	The	researchers	measured	the	
motor	function	using	the	Fugl‐Meyer	motor	scale.	For	90	days,	59	of	the	118	
participants	received	one	20	milligram/kilogram	dose	per	day,	while	the	other	
participants	received	a	placebo.	Both	groups	underwent	rehabilitation	therapy,	
in	addition	to	pharmacologic	intervention.	Even	when	controlling	for	the	
presence	of	depressive	symptoms	and	thrombolytic	therapy,	the	data	from	the	
trial	showed	that	the	fluoxetine	group	showed	a	greater	degree	of	improvement	
over	the	placebo	group	(Chollet	et	al,	2011).	
	Because	the	current	pharmacologic	armamentarium	for	the	treatment	of	
strokes	is	so	meager,	any	potential	agent	that	could	be	of	assistance	would	have	
significant	clinical	impact.	I	believe	that	this	experiment	has	shown	the	potential	
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of	these	three	pharmacologic	agents,	and	hopefully,	future	experiments	will	
further	elucidate	the	utility	of	these	agents.		
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